idiopathic pulmonary fibrosis

News

Syndax shares fall as lung fibrosis drug fails trial

Syndax shares lost 17% of their value pre-market after the company said it abandoned development of axatilimab for idiopathic pulmonary fibrosis.

News

BMS eyes filings for idiopathic pulmonary fibrosis drug

Bristol Myers Squibb has reported phase 3 results with a new drug for idiopathic pulmonary fibrosis that could open the door to regulatory filings.

News

Brainomix AI lends weight to Endeavor Bio's IPF trial data

An AI-based imaging tool from Brainomix has been used to enrich data from a phase 2a trial of Endeavor's idiopathic pulmonary fibrosis drug taladegib.

News

UK first in Europe to clear Boehringer's IPF drug Jascayd

Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.

News

Pulmonary fibrosis drug developer Avalyn files IPO

Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.

News

Insilico ends 2025 with $293m Hong Kong IPO

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.

Syndax shares fall as lung fibrosis drug fails trial

BMS eyes filings for idiopathic pulmonary fibrosis drug

Brainomix AI lends weight to Endeavor Bio's IPF trial data

UK first in Europe to clear Boehringer's IPF drug Jascayd

Pulmonary fibrosis drug developer Avalyn files IPO

Insilico ends 2025 with $293m Hong Kong IPO

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

idiopathic pulmonary fibrosis

Editor's Picks